Roche announced that the Phase III IMpassion131 study, evaluating Tecentriq® in combination with paclitaxel, in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-free survival for the initial treatment of people with metastatic triple-negative breast cancer, in the PD-L1-positive population.
Researchers summarized recent literature regarding molecules and pathways and reviewed the effects of cancer stem cells biology during the formation of brain metastasis in TNBC.
Researchers evaluated the effects and mechanisms of rosmarinic acid (RA) in two racially different TNBC cell lines. Results obtained showed that RA significantly caused cytotoxic and antiproliferative effects in both cell lines in a dose- and time-dependent manner. RA induced cell cycle arrest-related apoptosis and altered the expression of many apoptosis-involved genes differently.
[European Journal of Pharmacology]
6606345 63WXY4SE items 1 apa default asc 1
Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate, currently in Phase I clinical development for non-small cell lung cancer and TNBC.
[Daiichi Sankyo Ltd.]
Merck announced that the FDA has accepted two new supplemental Biologics License Applications for KEYTRUDA, Merck’s anti-PD-1 therapy.
The authors summarize recent literature regarding molecules and pathways and reviewed the effects of cancer stem cell biology during the formation of brain metastasis in triple-negative breast cancer.
Researchers generated and characterized traceable CAR T cells and examined potential negative effects of radionuclide reporter use. They applied the platform to two different triple-negative breast cancer models and unexpectedly observed pronounced differences in CAR-T tumor retention by PET/computed tomography and confirmed data ex vivo.
6445212 M26XZ984 items 1 apa default asc 1
Volpe, A., Lang, C., Lim, L., Man, F., Kurtys, E., Ashmore-Harris, C., Johnson, P., Skourti, E., Rosales, R. T. M. de, & Fruhwirth, G. O. (2020). Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models. Molecular Therapy, 0(0). https://doi.org/10.1016/j.ymthe.2020.06.028 Cite
The authors investigated spheroid-forming cells in a metastatic triple-negative breast cancer model. This strategy enabled them to specifically study a population of long-lived tumor cells enriched in cancer stem-like cells, which showed stem-like characteristics and induce metastases.
1254621 MCSJMNKA items 1 apa default asc 1
Scientists performed studies of viability, type of cell death, cancer stem cell percent and glycosphingolipid expression on CSC and non-CSC after treatment of MDA-MB-231 and MDA-MB-453 triple-negative breast cancer cells with a newly developed thienopyridine anticancer compound.
1254621 4A52DFSB items 1 apa default asc 1
Scientists showed that LEFTY1, a secreted inhibitor of NODAL/SMAD2 signaling, was produced by mammary progenitor cells and, concomitantly, suppresses SMAD2 and SMAD5 signaling to promote long-term proliferation of normal and malignant mammary epithelial cells.
[Cell Stem Cell]
1254621 5PE8GSVS items 1 apa default asc 1
Cyclophosphamide (CTX) increased expression of tumor cell PD-L1; however, when combined with concomitant PD-L1 antibody therapy none of the CTX regimens showed increased benefit.
[NPJ Breast Cancer]
Investigators demonstrated that changes in the expression of Yes-associated protein and β-catenin might be a promising predictive biomarker for neoadjuvant chemotherapy sensitivity in TNBC patients.
[Cell Death & Disease]
6606345 E5TY2IZY items 1 apa default asc 1